Blueprint Medicines Corporation (NASDAQ:BPMC) changed -1.68% to recent value of $79.74. The stock transacted 729460 shares during most recent day however it has an average volume of 548.63K shares. It spotted trading -22.57% off 52-week high price. On the other end, the stock has been noted 21.93% away from the low price over the last 52-weeks.
On Jan. 21, 2020, Blueprint Medicines Corporation (NASDAQ:BPMC) a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, notified that it has commenced an underwritten public offering of $325,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional $48,750,000 in shares of its common stock in connection with the public offering. All shares of common stock will be offered by Blueprint Medicines.
Blueprint Medicines expects to use the net proceeds of the offering to further build its global commercial infrastructure to support additional planned regulatory filings and commercial launches for AYVAKIT and pralsetinib, if approved, in the U.S. and Europe; to fund clinical trials for avapritinib in systemic mastocytosis (SM), including its ongoing registration-enabling Phase 2 PIONEER clinical trial for indolent and smoldering SM, as well as future indication expansion clinical trials; to fund clinical trials for pralsetinib in RET-driven cancers, including its Phase 3 AcceleRET Lung clinical trial for pralsetinib in first-line RET-altered NSCLC and its planned Phase 3 clinical trial for pralsetinib in first-line RET-mutant MTC, as well as future indication expansion clinical trials; to fund its planned Phase 1 trial for BLU-263 in healthy volunteers and future clinical trials for BLU-263 and other future drug candidates; to fund manufacturing costs for AYVAKIT and for ongoing and anticipated drug development efforts for its most advanced drug candidates; and the balance, if any, to fund additional discovery research efforts, its other ongoing and planned clinical trials, working capital requirements and other general corporate purposes.
Its earnings per share (EPS) expected to touch remained -37.60% for this year while earning per share for the next 5-years is expected to reach at 22.27%.
The company has 48.78M of outstanding shares and 47.97M shares were floated in the market. According to the most recent quarter its current ratio was 5.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of -0.85% from the mean of 20 days, 3.19% from mean of 50 days SMA and performed -1.78% from mean of 200 days price. Company’s performance for the week was 5.42%, 1.87% for month and YTD performance remained -0.46%.